Your browser doesn't support javascript.
loading
Transepithelial phototherapeutic keratectomy for treatment-resistant recurrent corneal erosion syndrome.
Bizrah, Mukhtar; Shunmugam, Maheshver; Ching, Geoffrey; Patel, Radhika P; Din, Nizar; Lin, David T C; Holland, Simon P.
Afiliação
  • Bizrah M; Imperial College Healthcare NHS Trust, Western Eye Hospital, 153-173 Marylebone Road, London, NW1 5QH, UK. m.bizrah@nhs.net.
  • Shunmugam M; The Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, Canada. m.bizrah@nhs.net.
  • Ching G; The Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, Canada.
  • Patel RP; The Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, Canada.
  • Din N; Imperial College Healthcare NHS Trust, Western Eye Hospital, 153-173 Marylebone Road, London, NW1 5QH, UK. Radhika.patel6@nhs.net.
  • Lin DTC; Imperial College London, London, UK. Radhika.patel6@nhs.net.
  • Holland SP; Imperial College Healthcare NHS Trust, Western Eye Hospital, 153-173 Marylebone Road, London, NW1 5QH, UK.
Article em En | MEDLINE | ID: mdl-38619603
ABSTRACT

BACKGROUND:

To evaluate the efficacy and safety of trans-epithelial phototherapeutic keratectomy (TE-PTK) as a treatment for recurrent corneal erosion syndrome (RCES) in patients with symptoms refractory to conventional treatments.

METHODS:

All patients who received TE-PTK treatment for RCES had failed 3 or more conventional treatments and were reviewed, and if met criteria, approved by healthcare workers of the British Columbia public health authority (Medical Services Plan (MSP). A retrospective chart review and telephone survey were conducted at the Pacific Laser Eye Centre (PLEC). Exclusion criteria were ocular co-morbidities potentially affecting treatment efficacy.

RESULTS:

This study included 593 eyes of 555 patients (46.2% male; 50.9 ± 14.2 years old) who underwent TE-PTK. The leading identified causes of RCES were trauma (45.7%) and anterior basement membrane dystrophy (44.2%). The most common pre-PTK interventions were ocular lubricants (90.9%), hypertonic solutions (77.9%), and bandage contact lenses (50.9%). Thirty-six eyes had undergone surgical interventions such as stromal puncture, epithelial debridement, or diamond burr polishing. Post-PTK, 78% of patients did not require any subsequent therapies and 20% required ongoing drops. Six patients (1.1%) reported no symptom improvement and required repeat TE-PTK for ongoing RCES symptoms after initial TE-PTK. All 6 eyes were successfully retreated with TE-PTK (average time to retreatment was 11.3 ± 14.9 months). There was no significant difference in best corrected visual acuity pre- vs. post-operatively. The mean post-operative follow-up was 60.5 months (range 5-127 months).

CONCLUSION:

TE-PTK has a good efficacy and safety profile for treatment-resistant RCES. The third-party public health-reviewed nature of this study, the low recurrence rate of RCES, and the low PTK retreatment rate suggest that TE-PTK might be considered for wider use in the management of RCES.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article